Wall Street brokerages expect Eagle Pharmaceuticals Inc (NASDAQ:EGRX) to announce sales of $51.15 million for the current quarter, according to Zacks. Two analysts have made estimates for Eagle Pharmaceuticals’ earnings. The highest sales estimate is $52.40 million and the lowest is $49.90 million. Eagle Pharmaceuticals reported sales of $46.79 million during the same quarter last year, which would suggest a positive year over year growth rate of 9.3%. The business is scheduled to announce its next quarterly earnings results on Monday, February 25th.

On average, analysts expect that Eagle Pharmaceuticals will report full year sales of $208.40 million for the current fiscal year, with estimates ranging from $207.20 million to $209.60 million. For the next financial year, analysts expect that the firm will post sales of $235.15 million, with estimates ranging from $219.80 million to $250.50 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for Eagle Pharmaceuticals.

Eagle Pharmaceuticals (NASDAQ:EGRX) last released its quarterly earnings data on Thursday, November 1st. The specialty pharmaceutical company reported $1.18 EPS for the quarter, beating the Zacks’ consensus estimate of $0.91 by $0.27. Eagle Pharmaceuticals had a net margin of 13.92% and a return on equity of 17.62%. The business had revenue of $51.34 million during the quarter, compared to analysts’ expectations of $52.70 million. During the same quarter in the prior year, the company earned $1.22 EPS. The firm’s quarterly revenue was down 18.5% on a year-over-year basis.

EGRX has been the subject of a number of recent analyst reports. TheStreet upgraded shares of Eagle Pharmaceuticals from a “c” rating to a “b-” rating in a research report on Thursday, August 9th. Royal Bank of Canada set a $84.00 price objective on shares of Eagle Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 8th. Piper Jaffray Companies set a $88.00 price objective on shares of Eagle Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, August 7th. Cantor Fitzgerald set a $81.00 price objective on shares of Eagle Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, August 7th. Finally, BidaskClub cut shares of Eagle Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 25th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $77.17.

EGRX opened at $50.61 on Wednesday. The company has a debt-to-equity ratio of 0.20, a current ratio of 5.59 and a quick ratio of 5.38. Eagle Pharmaceuticals has a 12 month low of $46.88 and a 12 month high of $85.66. The firm has a market capitalization of $774.74 million, a P/E ratio of 15.02 and a beta of 1.72.

A number of hedge funds and other institutional investors have recently made changes to their positions in EGRX. Wells Fargo & Company MN boosted its stake in Eagle Pharmaceuticals by 14.4% in the 1st quarter. Wells Fargo & Company MN now owns 23,287 shares of the specialty pharmaceutical company’s stock worth $1,228,000 after purchasing an additional 2,936 shares during the period. Russell Investments Group Ltd. boosted its stake in Eagle Pharmaceuticals by 563.5% in the 1st quarter. Russell Investments Group Ltd. now owns 5,779 shares of the specialty pharmaceutical company’s stock worth $304,000 after purchasing an additional 4,908 shares during the period. UBS Group AG boosted its stake in Eagle Pharmaceuticals by 362.1% in the 1st quarter. UBS Group AG now owns 47,980 shares of the specialty pharmaceutical company’s stock worth $2,528,000 after purchasing an additional 37,597 shares during the period. Principal Financial Group Inc. boosted its stake in Eagle Pharmaceuticals by 3.4% in the 1st quarter. Principal Financial Group Inc. now owns 73,885 shares of the specialty pharmaceutical company’s stock worth $3,893,000 after purchasing an additional 2,436 shares during the period. Finally, Louisiana State Employees Retirement System acquired a new position in Eagle Pharmaceuticals in the 2nd quarter worth $280,000. 97.91% of the stock is owned by hedge funds and other institutional investors.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL).

Recommended Story: Conference Calls and Individual Investors

Get a free copy of the Zacks research report on Eagle Pharmaceuticals (EGRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Eagle Pharmaceuticals (NASDAQ:EGRX)

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.